Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Arrowhead Pharmaceuticals ( (ARWR) ) is now available.
On September 2, 2025, Arrowhead Pharmaceuticals entered into an exclusive licensing and collaboration agreement with Novartis Pharma AG for ARO-SNCA, a preclinical stage RNA interference therapeutic for Parkinson’s Disease. Arrowhead will receive a $200 million upfront payment and could earn up to $2 billion in milestone payments, with Novartis taking responsibility for clinical development and commercialization. This partnership highlights Arrowhead’s strategic positioning in the CNS space and the potential impact of its TRiMTM platform in advancing treatments for neurodegenerative diseases.
The most recent analyst rating on (ARWR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is primarily influenced by its challenging financial performance, characterized by negative profitability and cash flow metrics. Despite these challenges, the stock’s technical indicators show positive momentum, which partially offsets the financial concerns. Valuation remains a concern due to ongoing losses and lack of dividends. The earnings call provided a cautiously optimistic outlook, but it was not factored into the score due to the methodology.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Utilizing a broad portfolio of RNA chemistries and efficient delivery modes, Arrowhead’s therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
Average Trading Volume: 2,016,519
Technical Sentiment Signal: Hold
Current Market Cap: $3.05B
For a thorough assessment of ARWR stock, go to TipRanks’ Stock Analysis page.